comparemela.com

Latest Breaking News On - Science regulatory affairs at novaliq - Page 1 : comparemela.com

Novaliq GmbH: Novaliq Announces FDA Approval of VEVYE (Cyclosporine Ophthalmic Solution) 0 1% for the Treatment of the Signs and Symptoms of Dry Eye Disease

VEVYE is the first and only cyclosporine solution indicated for the treatment of signs and symptoms of dry eye disease with efficacy demonstrated after 4 weeks Novaliq GmbH, a biopharmaceutical company

Mecklenburg vorpommernUnited statesBaden wübergUnited kingdomJohnd sheppardStefan klotterChristian roeskyNovaliq gmbSimone angstmann mehrDrug administrationHealth sciencesGmbh coScience regulatory affairs at novaliqMcdonald eye associatesIntrepid eye societyNovaliq inc

Water-Free Dry Eye Disease Therapy Vevye Gets FDA Approval

The FDA has approved Vevye (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of dry eye disease.

Drug administrationScience regulatory affairs at novaliqVice president medical scienceRegulatory affairs

vimarsana © 2020. All Rights Reserved.